RxDoctor Payments Data

William Jordan, DO

Ophthalmology · Scranton, PANPI 1922110766

Payments from drug & device makers

$5,207in general payments, 2019–2025

Across 102 payments — averaging $51.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson Surgical Vision, Inc.$2K
  • Carl Zeiss Meditec, Inc.$854
  • NEW World Medical,inc.$742
  • Alcon$407
  • AbbVie$293
  • AstraZeneca$125
  • plus $769 from 12 others

What the payments were for

  • Consulting fees$1,13222%
  • Food & beverage$3,22162%
  • Gifts$85416%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,207 in reported general payments places this provider in the 75th percentile of 920 ophthalmology providers in Pennsylvania.

See all ophthalmology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$438,005
Medicare patients
1,301
Services billed
2,817

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine123$153,382
RocklatanNetarsudil Mesylat/Latanoprost196$91,196
Cyclosporine113$66,895
LumiganBimatoprost150$52,891
XiidraLifitegrast28$35,387
SimbrinzaBrinzolamide/Brimonidine Tart90$22,920
CombiganBrimonidine Tartrate/Timolol79$22,661
RhopressaNetarsudil Mesylate27$16,060
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol128$13,226
Timolol Maleate207$11,566
TyrvayaVarenicline Tartrate19$11,440
Latanoprost1,038$10,918
Brimonidine Tartrate153$9,992
Alphagan PBrimonidine Tartrate19$6,164
Travoprost34$4,924

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan, Alphagan P$293$235,098371 claims
Bausch & Lomb Americas Inc.Xiidra$33$35,38728 claims
AlconSimbrinza$407$22,92090 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 920 ophthalmology providers in Pennsylvania.

Other ophthalmology in Scranton

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →